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Abstract
Introduction: Gene profiling may improve prognostic accuracy in patients with early breast cancer, but this technology is
not widely available. We used commercial assays for qRT-PCR to assess the performance of the gene profiles included in the
70-Gene Signature, the Recurrence Score and the Two-Gene Ratio.
Methods: 153 patients with early breast cancer and a minimum follow-up of 5 years were included. All tumours were
positive for hormonal receptors and 38% had positive lymph nodes; 64% of patients received adjuvant chemotherapy. RNA
was extracted from formalin-fixed paraffin-embedded (FFPE) specimens using a specific kit. qRT-PCR amplifications were
performed with TaqMan Gene Expression Assays products. We applied the three gene-expression-based models to our
patient cohort to compare the predictions derived from these gene sets.
Results: After a median follow-up of 91 months, 22% of patients relapsed. The distant metastasis-free survival (DMFS) at 5
years was calculated for each profile. For the 70-Gene Signature, DMFS was 95% -good prognosis- versus 66% -poor
prognosis. In the case of the Recurrence Score, DMFS was 98%, 81% and 69% for low, intermediate and high-risk groups,
respectively. Finally, for the Two-Gene Ratio, DMFS was 86% versus 70%. The 70-Gene Signature and the Recurrence Score
were highly informative in identifying patients with distant metastasis, even in multivariate analysis.
Conclusion: Commercially available assays for qRT-PCR can be used to assess the prognostic utility of previously published
gene expression profiles in FFPE material from patients with early breast cancer. Our results, with the use of a different
platform and with different material, confirm the robustness of the 70-Gene Signature and represent an independent test
for the Recurrence Score, using different primer/probe sets.
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Introduction
A key area in the management of women with early breast
cancer is the selection of adjuvant therapy, which depends on
the use of prognostic and predictive factors. Chemotherapy is
usually recommended in the presence of adverse factors, such as
positive lymph nodes, size.1 cm, histological grade.1o r
negative hormonal receptors. These factors are included in
guidelines or specific software to help decision making [1,2], but
using these criteria leads to unnecessary treatment in many
women, either because they would not relapse in the absence of
adjuvant chemotherapy or because they would suffer a relapse
anyway [3].
Gene expression profiles may improve prognostic and predictive
information in breast cancer patients. Two of these profiles, the
70-Gene Signature (MammaPrint
TM) and the Recurrence Score
(OncoType DX
TM) are being evaluated in phase III studies, with
randomization based on the results of the assays [4,5]. The 70-
Gene Signature is suitable for patients with either ER-positive or
ER-negative tumours, whereas the Recurrence Score has to be
used in ER-positive tumours. Another group has reported a Two-
Gene Ratio (HOXB13/IL17BR) predicting disease-free survival in
patients with early-stage, ER-positive breast cancer who received
adjuvant tamoxifen [6]. An RT-PCR based method to assess this
ratio from paraffin-embedded tissue samples is now commercially
available (Theros H/I; bioTheranostics).
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very low risk of relapse who may not need adjuvant chemotherapy.
The major restraints for the widespread application of such tests are
some reservations regarding their cost/effectiveness ratio and the lack
ofavailability, becausesamplesmust besentto centrallaboratoriesfor
processing.Theneedforfresh-frozen(FF)materialinsomecasesadds
to these restraints, as the process of collecting, processing and storing
FF samples for large scalestudies is difficult. However,the use of gene
profiles would be facilitated if centralized processing was not required
and formalin-fixed paraffin-embedded (FFPE) samples could be used.
FFPE samples are stable at room temperature, easily storable and,
most importantly, they constitute a widely available archive of clinical
samples linked to clinical information.
In the present study, we assessed the performance of the above
referred gene expression profiles by using commercially available
assays for qRT-PCR in FFPE samples.
Results
One hundred fifty-three patients diagnosed between February-
95 and March-03 were included. Table 1 shows their clinical
features. Median age was 58 years and median follow-up was 91
months for the whole group. Sixty-six patients (43%) had a
mastectomy, whereas the remaining underwent a conservative
surgery followed by adjuvant radiation. All patients received
adjuvant tamoxifen for five years and 97 (63%) underwent
adjuvant chemotherapy. Thirty-four patients (22%) had a distant
relapse, of which 17 died and 7 were lost for follow-up after the
relapse. Among 119 patients without distant relapse, four had a
local/regional recurrence successfully treated with surgery.
qRT-PCR reactions worked correctly for all genes included in
the Recurrence Score, both genes of the Two-Gene Ratio, and all
60 we could include from the 70-Gene Signature. Raw data
appear in supplementary Table S1. In the univariate analysis,
lymph-node status, tumour grade, size and the three gene profiles
were significant predictors of DMFS (lymph-node status p=0.001;
tumour grade p,0.001; size p=0.002; 70-Gene Signature
p,0.001; Recurrence Score,0.001; Two-gene Ratio p=0.023).
DMFS at five years for every profile was as follows: for the 70-
Gene Signature, 95% good prognosis versus 66% poor prognosis;
for the Recurrence Score profile, 98% low-risk versus 81%
intermediate risk versus 69% high-risk; and in the case of the Two-
Gene Ratio, 86% favourable versus 70% unfavourable (figure 1).
We restricted the univariate analysis to patients who did not
receive adjuvant chemotherapy and the three profiles still found
significant differences (figure 2).
Cramer’s V statistic was performed in the profile-to-profile
comparison and, for this purpose, we combined the low and
intermediate Recurrence Score categories. The concordance of
the Two-Gene Ratio with either the 70-Gene Signature or the
Recurrence Score was 0.3 in both cases. Concordance was 0.6
between the 70-Gene Signature and the Recurrence Score,
indicating a strong correlation. Most tumours classified as having
a low risk of recurrence by one the three models were classified as
such by the other two, although the low-risk group defined by the
Two-Gene Ratio was poorly predicted by the 70-Gene Signature
and the Recurrence Score. When comparing high risk tumours,
again there was a good correlation between the 70-Gene Signature
and the Recurrence Score, but rather poor for the Two-Gene
Ratio. Table 2 shows the intersection between profiles.
To assess the discrimination capability of each prognostic profile
at 5 years, Harrell’s bias corrected concordance index was
calculated. The values were: Recurrence Score=0.73.70-Gene
Signature=0.70.Two-Gene Ratio=0.59.
We also performed a multivariate Cox proportional hazards
analysis to evaluate the prognostic value of each gene-expression
based model individually. The analysis also included tumour size,
nodal status and tumour grade. The 70-Gene Signature and the
Recurrence Score were significant predictors of DMFS (Table S2,
supporting information), indicating that those gene expression
profiles added important prognostic information beyond that
provided by clinical factors. The Two-Gene Ratio was not a
significant predictor in the multivariate analysis. Node status
remained the only clinical factor with significant value in all cases.
Histological grade was significant for the cases of Recurrence
Score (p=0.043) and Two-Gene Ratio (p=0.002).
Likewise, the 70-Gene Signature and the Recurrence Score
detected striking differences for the subgroup of patients with
positive lymph nodes, whereas differences were not significant in
the case of the Two-Gene Ratio (figure 3).
Adjuvant! Online estimated that chemotherapy would reduce
the rate of relapse by less than 5% in 37% of patients. A threshold
of 5% was selected because it is used by many clinicians to
discourage the use of chemotherapy. By contrast, the three gene
profiles allocated more patients in low-risk groups: 46% the 70-
Gene Signature, 53% the Recurrence Score (low + intermediate
risk) and 73% the Two-Gene Ratio. The multivariate analysis
including Adjuvant! Online showed that both the 70-Gene
Signature and the Recurrence Score remained significant
Table 1. Clinical characteristics of the patients.
Number of patients (percentage)
Age Median 58, range: 29–82
T
1 77 (50.3%)
2 76 (49.7%)
N
0 96 (62.7%)
1 57 (37.3%)
Stage
I 61 (39.9%)
IIa 51 (33.3%)
IIb 41 (26.8%)
Hormone receptors
ER+/PgR2 30 (19.6%)
ER+/PgR+ 110 (71.9%)
ER+/PgR unknown 12 (7.9%)
ER2/PgR+ 1 (0.7%)
Grade
1 29 (18.9%)
2 64 (41.8%)
3 59 (38.6%)
x 1 (0.7%)
Chemotherapy
No chemotherapy 56 (36.6%)
CMF 42 (27.4%)
Anthracycline-based 55 (35.9%)
All tumours were positive for oestrogen and/or progesterone receptors. All
patients had received adjuvant tamoxifen.
doi:10.1371/journal.pone.0005911.t001
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Breast Cancer Gene Profiles
PLoS ONE | www.plosone.org 3 June 2009 | Volume 4 | Issue 6 | e5911Figure 2. Survival analysis in patients who did not receive chemotherapy.
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(Table 3). In our population, the Nottingham Prognosis Index
did not show significant value to define prognosis in the univariate
analysis (p=0.061), so that it was not included in the multivariate
analysis.
The gain in predictive accuracy from adding each of the
analyzed signatures to the Nottingham Prognostic Index and
Adjuvant! Online clinical systems is presented in Table 4. The
individual performance for DMFS of Nottingham Prognostic
Index and Adjuvant! Online was comparable (0.239 and 0.236,
respectively). The performance of the 70-Gene Signature (0.234)
was in line with that of both clinical staging systems, whereas the
Recurrence Score showed the best performance (0.225). The
addition of the 70-Gene Signature and the Recurrence Score to
any of the clinical staging systems decreased their predictive
inaccuracy. The gain by adding the 70-Gene Signature in
explained variation was 9.2%, and over 10% for the Recurrence
Score in this dataset. The Two-Gene Ratio did not improve the
clinical staging systems explained variation.
Discussion
Gene profiles help to determine prognosis in patients with early
breast cancer and some of them are being used to make clinical
decisions. If gene profiles become part of the standard pathological
workup in early breast cancer in the future, general availability will
be required and the use of FFPE material would be very useful.
Several studies have demonstrated the feasibility of using FFPE
tissues to perform gene expression profiling by qRT-PCR.
Although RNA degradation leads to a loss of amplifiable
templates, optimized normalization strategies could effectively
compensate for this bias [4,7,8].
We compared the performance of three gene profiles -70-Gene
Signature, Recurrence Score and Two-Gene Ratio- in patients
with early breast cancer. The material was FFPE tissue and the
technique qRT-PCR in all cases, in an attempt to simplify
technical procedures. The 70-Gene Signature was initially
described in young women who had not received adjuvant
therapy, but further research has confirmed its validity in other
groups [5,9,10,11], and its applicability in patients with either
positive or negative hormonal receptors [12]. On the other hand,
the Recurrence Score is aimed at tumours expressing hormonal
receptors and provides prognostic and predictive information in
patients treated with tamoxifen [4,13,14]. The Two-Gene Ratio
was developed and validated in early-stage hormonal receptor
positive patients that had received adjuvant tamoxifen therapy
[6,15]. So the populations where each of these profiles was initially
described vary according to their clinical, pathological and
therapeutic features, thus hindering any direct comparison. In
our study, the three profiles identified groups of patients with
significant differences in DMFS, although only the 70-Gene
Signature and the Recurrence Score offered significant value in
the multivariate analysis, showing a high correlation between
them. The other profile -Two-Gene Ratio- has recently been
improved by incorporating five genes related to tumour grade
[16]. This five-gene set was comparable to a more complex 97-
gene genomic grade index in multiple data sets [17].
Clinical comparisons have not been performed among profiles,
although one study by Fan et al. evaluated five gene sets in a data
set of patients [18]. This study demonstrated significant agreement
among four out of the five profiles, namely, intrinsic subtypes, 70-
Gene Signature, Recurrence Score and Wound-Signature. The
conclusion was that they probably track a common set of biologic
phenotypes. In agreement with the study by Fan et al, we find a
high concordance between the 70-Gene Signature and the
Recurrence Score and a lack of reproducibility of the Two-Gene
Ratio. However, there are important differences between both
studies. Firstly, we hereby present an independent set of patients
who received more aggressive therapy than those included in the
other study; this could have improved outcome in our patients.
Secondly, all of our samples derived from FFPE tissue. Thirdly,
the technique we used was qRT-PCR for the three profiles,
whereas Fan et al used the original assay for the 70-Gene
Signature and translated the PCR values of the Recurrence Score
into a microarray dataset. In other words, we used a different
platform for the 70-Gene Signature and different, commercial
available probes for the Recurrence Score. To our knowledge, our
study is the first fully independent application of the Recurrence
Score algorithm, because other investigators sent samples to a
central laboratory for processing [19].
Fan et al. showed that microarray data would be applicable to
assess the Recurrence Score and the Two-Gene Ratio (originally
developed with PCR), so the opposite assumption may be also
correct. On the other hand, we previously demonstrated that
qRT-PCR can be used to assess the 70-Gene Signature profile
[20]. Likewise, the present study proves that the 70-Gene
Signature can also be determined from FFPE material. This work
solves a technical difference that gave certain advantage to the
Recurrence Score over the 70-Gene Signature in their attempt to
burst in the clinic, i.e., the use of FFPE material. Our results with
the use of a different platform and with different material confirm
the robustness of the 70-Gene Signature and the Recurrence
Score. In other words, the value of these profiles cannot be
attributed to the use of a specific platform, but to the algorithms
and the genes themselves. Our results are in agreement with those
of other investigators seeing that previously reported prognostic
signatures, despite differences in gene lists, carry similar prognostic
information [21,22].
In our series, gene profiles outperformed clinical data to identify
patients with low risk of relapse. The use of Adjuvant! Online
would have led to recommend chemotherapy in 63% of patients
whereas few patients lied in high-risk groups determined by gene
expression profiles. A recent study with hormone receptor-positive
breast cancer and zero to three positive axillary nodes also
demonstrated that the Recurrence Score is a more accurate
predictor of relapse than standard features included in Adjuvant!
Table 2. Concordance among the three profiles.
Good prognosis by… Coincidence cases Coincidence cases
70-Gene Signature Recurrence Score Two-Gene Ratio
n=83; 54% n=66; 79% n=71; 85%
Recurrence Score 70-Gene Signature Two-Gene Ratio
n=81; 53% n=66; 81% n=68; 84%
Two-Gene Ratio 70-Gene Signature Recurrence Score
n=112; 73% n=71; 63% n=68; 61%
Poor prognosis by… Coincidence cases Coincidence cases
70-Gene Signature Recurrence Score Two-Gene Ratio
n=70; 46% n=55; 78% n=29; 41%
Recurrence Score 70-Gene Signature Two-Gene Ratio
n=72; 47% n=55: 76% n=28; 39%
Two-Gene Ratio 70-Gene Signature Recurrence Score
n=41; 27% n=29; 71% n=28; 68%
doi:10.1371/journal.pone.0005911.t002
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of patients with small tumours and none or up to three positive
lymph nodes, i.e., good prognosis tumours. Differences could have
been bigger in a non-selected population including tumours with
unfavourable clinical features, as shown in other studies [13,24].
Although subgroup analysis must be viewed with caution, we also
found that in patients with positive lymph nodes, a favourable 70-
Gene Signature or a low-risk Recurrence Score was still associated
with an excellent prognosis. Similar results were seen in the group
not receiving chemotherapy.
Additionally, we showed that the Recurrence Score and the 70-
Gene Signature improved the predictive accuracy of commonly
used clinical systems, whereas the Two-Gene Ratio did not. This is
relevant because experts in the field agree that these new
techniques should provide more accurate information than
classical factors to be incorporated into clinical practice.
Moreover, these gene expression classifiers should not be regarded
as a tool to replace standard pathological and clinical criteria, but
should instead be integrated with clinical parameters [25].
Phase III trials have been initiated to determine whether two of
them –the 70-Gene Signature and the Recurrence Score- may
reduce the need for adjuvant chemotherapy in patients withlow risk
of relapse. Of course, this does not support the indiscriminate use of
this new technology in the clinic, at least by present standards. But if
phase III trials demonstrate the validity of either the 70-Gene
Signature or the Recurrence Score, a substantial number of patients
could be treated without adjuvant chemotherapy in the future.
Patients with N0 disease would benefit first from this strategy, as
many of them (particularly young women) are offered chemother-
apy if there is an adverse factor, such as high grade or size .2 cm.
There is also a possibility that some patients with positive lymph
nodes could do so in the future. The field is evolving very rapidly
andnewcontributionswillbeneededtoimprovetheaccuracyofthe
information provided by currently available profiles.
In summary, we verified the performance of some gene profiles,
particularly the 70-Gene Signature and the Recurrence Score by
using qRT-PCR in FFPE samples with commercially available
assays. Our study opens the possibility to simplify the procedures
to perform high-throughput techniques in the general population
of patients with breast carcinoma. However, before this technology
is taken to the clinic, ongoing phase III trials should validate the
utility of prognostic gene profiles.
Materials and Methods
Ethics statement
At the time of initial diagnosis, all patients had provided consent
in the sense that their tumour samples could be used for
Table 3. Multivariate analysis comparing Adjuvant! Online
with gene expression classifiers.
Adjuvant! Online
HR CI 95% p value
Adjuvant! Online 10.814 2.589–45.173 0.001
70-Gene Signature 4.218 1.800–9.883 0.001
Adjuvant! Online 7.458 1.764–31.533 0.006
Recurrence Score 0.003
(Interm. risk vs. Low risk) 4.132 0.745–22.906 0.105
(High risk vs. Low risk) 10.098 2.343–43.518 0.002
Adjuvant! Online 6.451 1.529–27.226 0.011
Two-Gene Ratio 1.864 0.932–3.727 0.078
Adjuvant! Online 10.051 2.400–42.101 0.002
doi:10.1371/journal.pone.0005911.t003
Table 4. Explained variation and predictive inaccuracy for DMFS.
Predicitve inaccuracy Explained variation (%)
No Predictor 0.275
NPI 0.23960.006 13.361.0
Adjuvant! 0.23660.002 13.960.9
70-Gene S. 0.23460.003 14.861.0
RS 0.22560.003 18.160.9
Two-Gene Ratio 0.26460.002 3.460.9
NPI & 70-Gene S. 0.21360.004 22.461.3
Adjuvant! & 70-Gene S. 0.21160.003 23.161.2
NPI & RS 0.21060.005 23.761.5
Adjuvant! & RS 0.20460.004 25.861.4
NPI & Two-Gene Ratio 0.23760.006 13.861.5
Adjuvant! & Two-Gene Ratio 0.23260.004 15.561.5
Gain by adding 70-Gene S. to NPI 0.025 9.2
Gain by adding 70-Gene S. to Adjuvant! 0.025 9.2
Gain by adding RS to NPI 0.028 10.4
Gain by adding RS to Adjuvant! 0.033 11.8
Gain by adding Two-Gene Ratio to NPI 0.001 0.5
Gain by adding Two-Gene Ratio to Adjuvant! 0.004 1.5
NPI: Nottingham Prognostic Index, RS: Recurrence Score, 70-Gene S.: 70-Gene Signature. Data presented as the mean6standard error.
doi:10.1371/journal.pone.0005911.t004
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committee was obtained for the conduct of the study (Comite ´
E ´tico de Investigacio ´n Clı ´nica). Data were analyzed anonymously.
Patients provided written consent so that their samples and clinical
data could be used for investigational purposes.
Patients and clinical data
The study population consisted of women with early breast
cancer. Inclusion criteria were: invasive ductal carcinoma, stage I
or II (TNM classification, 2002), positive for oestrogen and/or
progesterone receptors and appropriate therapy. Appropriate
therapy should include either mastectomy or tumorectomy plus
adjuvant radiotherapy, adjuvant hormonal therapy for 5 years in
all patients, and adjuvant anthracycline-based chemotherapy in
N+ or in N0 patients with poor prognostic features. A minimum
follow-up of 5 years was also required. The following data were
recorded and tabulated: age at diagnosis, size of primary tumour,
lymph node stage, number of positive nodes, grade of differen-
tiation, hormonal receptors, adjuvant therapy (either radiation,
hormones or chemotherapy), date of relapse or last follow-up, site
of relapse, cause of death.
RNA Isolation and cDNA Synthesis
An experienced pathologist evaluated H&E preparations to
select samples with at least 70% of tumour cells. Fifteen sections
5 mm each from every FFPE sample were deparaffinized with
xylene and washed with ethanol in decreasing concentrations
(100%, 90% and 70%). RNA was then extracted with the Master
Pure
TM Kit (Epicentre).
Isolated total RNA was quantified and qualitatively assessed
using spectrophotometer OD260 measurements and agarose gel
electrophoresis. We normalized to total RNA input; therefore,
first-strand cDNA was synthesized from 1 mg of total RNA, using
random primers, according to the High Capacity cDNA Reverse
Transcription Kit protocol (Applied Biosystems). The complete
reaction mixes were incubated at 25uC for 10 min and 37uC for
120 min.
Quantitative RT-PCR
qRT-PCR amplifications were performed with TaqMan Gene
Expression Assays products in an ABI PRISM 7900 HT Sequence
Detection System (Applied Biosystems). The reactions were
carried out using the TaqMan Low Density Arrays (TLDAs,
Applied Biosystems) containing 50 mL TaqMan Universal PCR
Master Mix (Applied Biosystems) and 50 mL of a cDNA template
corresponding to 100 ng total RNA per channel of the micro-
fluidic card.
Gene selection
We configured a TLDA series to analyze those genes included
in the 70-Gene Signature [5], the Recurrence Score [4] and the
Two-Gene Ratio [6] with TaqMan Gene Expression Assays
available. Table S1 (supporting information) shows the assays we
used to study the genes included in each profile as well as the
housekeeping genes.
Although RNA degradation in FFPE samples leads to a loss of
amplifiable templates, optimized normalization strategies can
effectively compensate for this bias [7,8]. We have generated a
normalization model called NorMean (unpublished data). This
model ranks housekeeping genes according to their capacity to
control for several levels of experimental variability in qRT-PCR.
Using this ranking, we calculated different normalization factors
by stepwise inclusion of control genes and geometric averaging of
their expression levels. The optimal number of control genes for
normalization was determined by comparing the percentage of
significantly correlated genes between FF and FFPE materials
using each normalization factor.
Calculations for gene expression profiles
Average cycling threshold (Ct) values, defined as the point at
which the fluorescence rises above the background fluorescence
[26], were obtained using the SDS 2.2 software (Applied
Biosystems). The maximum Ct value was set at 40. These Ct
values were recorded in Microsoft Excel 2003 for subsequent
calculations. The methods originally described for the 70-Gene
Signature [10], the Recurrence Score [4] and the Two-Gene
Ratio [6,15] were used to analyze the performance of these
profiles.
70-Gene Signature. Sixty out of the 70 genes were included
[10], as the remaining 10 were not available for TLDAs by the
time the experiment was performed. One previous study
demonstrated that a reduction of the signature had little impact
on the performance of the classifier [12]. Relative expression level
of each target gene was expressed as DCt=Ctref2Cttarget.
Normalization was performed using the geometric mean of the
best housekeeping gene set (IPO8, POLR2A, UBC and SDHA).
As the 70-gene signature was defined using microarrays,
normalized gene Cts values were z-score transformed. The mean
good-prognosis profile was calculated averaging the gene
expression values of each gene for the patients without
recurrence. Pearson’s correlation coefficient between this mean
good-prognosis profile and each patient’s gene expression profile
was calculated. A value threshold=0 was used, as previously
described [12]. Although the validity of calculating correlation
coefficients in this way is questionable [27], we decided to use it to
resemble as much as possible the methodology described by van’t
Veer et al [5] and others [12].
Recurrence Score. Briefly, expression of each gene was
normalized relative to the expression of the reference genes
(ACTB, GAPDH, GUS, RPLP0 and TFRC). Reference-
normalized expression measurements were calculated as
described by Paik et al., so that one unit increase in reference-
normalized expression measurements reflects approximately a 2-
fold increase in RNA. We substituted GSTM1 by GSTM3
because no GSTM1 probe was available for the TLDAs, as
described by the authors in the patent information (Baker J et al,
http://www.freepatentsonline.com/20050048542.html)
The RS algorithm was then used to generate an unscaled
Recurrence Score for each patient. Values were scaled and
patients were assigned to the low, intermediate or high-risk group
using the RS cut-offs previously described [4].
Two-Gene Ratio. Relative expression levels of HOXB13 and
IL17BR were expressed as DCt=Ctref2Cttarget. Cts for the four
reference genes (ACTB, HMBS, SDHA and UBC) were averaged
to obtain Ctref. These values were z-transformed for each gene and
the Two-Gene Ratio was calculated taking the difference and
using a cut off point of 1.0, as described [15].
Statistical Analysis
The prognostic value of each gene-expression–based model was
evaluated by log-rank test. We also applied multivariate Cox
proportional-hazards analysis to each profile individually in a
model including tumour grade (2 vs. 1 and 3 vs. 1), size (.2 cm vs.
#2 cm) and nodal status (one to three positive nodes vs. no
positive nodes). We also applied multivariate Cox analyses to each
profile in a model including all clinical parameters that resulted
significant in the univariate analysis. Distant metastasis-free
Breast Cancer Gene Profiles
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gene profiles in breast cancer.
Two-way contingency-table analyses and the calculation of
Cramer’s V statistic were also performed to measure the strength
of the association between the different profiles [18]. As both the
70-Gene Signature and the Two-Gene Ratio establish two groups
with high and low risk, this analysis required that the low and
intermediate groups of the Recurrence Score were combined.
To assess model accuracy (discrimination) at five years, Harrell’s
bias corrected concordance index was calculated. Models were
refit 500 times with the bootstrap resampling technique. The
concordance index is the percentage of patient pairs in which the
predicted and observed outcomes are in agreement; i.e., the
probability that for two patients chosen at random, the patient
who had the event first had a higher probability of having the
event according to the model. c=0.50 represents agreement by
chance; c=1.0 represents perfect discrimination [28]. Concor-
dance is essentially the Wilcoxon-Mann-Whitney statistic for
comparing predictions in the two outcome groups, and it is
identical to the area under a receiver operating characteristic
curve (ROC) [29].
The gain in predictive accuracy of each classifier, as compared
with common clinical staging systems, was investigated using the
method of Schemper and Henderson, implemented in the R
package software as previously described [21,25,30,31].
All statistical analyses were performed with the SPSS v9.1
software package, GraphPad Prism v5.00 and ‘‘R’’ v 2.2 with the
Design software package v2.0-12. All P values were two-sided, and
P,0.05 was considered statistically significant.
Supporting Information
Table S1 Assays and raw data.
Found at: doi:10.1371/journal.pone.0005911.s001 (0.34 MB
XLS)
Table S2 Multivariate analysis with individual clinical factors
Found at: doi:10.1371/journal.pone.0005911.s002 (0.05 MB
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